Global HPV associated disorder market is projected to grow at a considerable CAGR of around 5% during the forecast period (2020-2026). The high incidence and prevalence of HPV associated disorder in association with the high penetration of medication is a key aspect contributing to the growth of the global HPV associated disorder market. Cohesive government policies, increasing per capita healthcare expenditure and increase in awareness programs related to HPV associated disorder are further contributing towards the high growth of the global HPV associated disorder market.

The increasing HPV screening and testing along with providing vaccines to prevent the development of cancer cells are making a huge contribution to the development of the HPV-associated disorder market across the globe. Cervarix, Gardsil, Gardsil-9, and HEPLISAV-B are the US FDA approved preventive cancer vaccines. Bacillus Calmette-Guérin (BCG) and Sipuleucel-T (Provenge) are the therapeutic cancer vaccine. However, lack of awareness, stringent government regulations, and lack of novel therapies are the key factors anticipated to hinder the growth of the global HPV associated disorder market.

Segmental Outlook  

The HPV associated disorder market is segmented on the basis of indication and therapy type. Based on the indication, the market is segmented into Cervical Intraepithelial Neoplasia (CIN), cervical cancer, Anal Intraepithelial Neoplasia (AIN), anal cancer, and genital warts. Based on the indication type, the market is segmented into prevention and therapy. 

Cervical to be considerable segment based on Indication

The rising prevalence of cervical cancer among females along with the high performance of Avastin and Keytruda for its treatment is anticipated to make a major contribution towards the high share of this market segment. However, the early patent expiration and the entrance of similar biologics may restrain the growth of this market segment. CIN is anticipated to exhibit considerable growth based on the indication. The high prevalence of CIN due to having unprotected sex, multiple sex partners, and a sedentary lifestyle is a key factor driving the growth of this market segment.

Global HPV Associated Disorder Market Share by Indication, 2019 (%)

Regional Outlook 

The global HPV associated disorder market is further segmented on the basis of geography including North America, Europe, Asia-Pacific, and Rest of the World. North America is anticipated to hold a considerable market share during the forecast period. According to the Center for Disease and Control Prevention (CDC), nearly 44,000 HPV-associated cancers occur in the US every year, among them nearly 25,000 among women, and nearly 19,000 among men. The high incidence and prevalence rate of different types of cancers in the region is creating demand for such a market in the region. The presence of a substantial number and amount of funding for cancer-related researches in the US and Canada are contributing towards the market growth in the region. Furthermore, cohesive government policies and initiatives, increasing R&D funding to discover new therapies by key market players will further influence the regional business growth of the market. 

Global HPV Associated Disorder Market Growth, by Region 2020-2026

Asia-Pacific to exhibit considerable growth during the forecast period 2020-2026

Improving healthcare infrastructure, increasing per capita healthcare expenditure, rise in funding for cancer-related researches, along with the significant presence of patients suffering from the HPV associated disorders are anticipated to be the key factors driving the growth of the HPV associated disorder market in the Asia-Pacific region. According to the study of the National Center for Biotechnology Information (NCBI), the overall prevalence of HPV infection in the Indian women was 60.33%. The prevalence of HPV infection was 93.80% in invasive cervical cancer (ICC) cases, 54.32% in inflammatory smear and 19.11% in normal cervical cytology. However, the lack of awareness related to the treatment of this disorder among the low-income economies of the region is anticipated to restrain the growth of the HPV-associated disorder market in the region.

Market Players Outlook

The key players of HPV associated disorder market include Johnson & Johnson Services, Inc., Pfizer Inc., Merck & Company, Inc., GlaxoSmithKline Plc., Eli Lily and Company, F. Hoffmann-La Roche Ltd., AstraZeneca plc, Biocon Ltd., Novartis AG, and so on. These players are actively adopting different growth strategies such as new product launch, partnerships, collaboration, and mergers and acquisition among others to remain competitive in the market place. The major players of the HPV associated disorder market are making hefty investments in the R&D of new therapies to remain competitive in the market place. 

The Report Covers

• Market value data analysis of 2019 and forecast to 2026.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global HPV associated disorder market. Based on the availability of data, information related to the products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.